FDA Approves Anktiva for BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer
The novel drug is a first-in-class interleukin-15 agonist immunotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
The novel drug is a first-in-class interleukin-15 agonist immunotherapy
Only registered members have full access to PracticeUpdate content.